Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus-A case series and literature review.

IF 1.4 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
JRSM Cardiovascular Disease Pub Date : 2019-04-08 eCollection Date: 2019-01-01 DOI:10.1177/2048004019839548
Reem A Bahmaid, Shoroq Ammar, Sarah Al-Subaie, Mohammed A Soofi, Hassan Mhish, Madonna Ali Yahia
{"title":"Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus-A case series and literature review.","authors":"Reem A Bahmaid,&nbsp;Shoroq Ammar,&nbsp;Sarah Al-Subaie,&nbsp;Mohammed A Soofi,&nbsp;Hassan Mhish,&nbsp;Madonna Ali Yahia","doi":"10.1177/2048004019839548","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Left ventricular thrombus is a frequent complication of acute myocardial infarction and a risk factor for thromboembolic complications. Warfarin has been frequently used, but has some disadvantages that limit its use. Direct oral anticoagulants, in particular Dabigatran and Rivaroxaban have been proved to be effective in preventing thromboembolism among patients with non-valvular atrial fibrillation. However, no randomized clinical trials testing the efficacy and safety of these agents in patients with existing left ventricular thrombus. Furthermore, direct oral anticoagulants are still not approved by the Food and Drug Administration in the management of left ventricular thrombus.</p><p><strong>Method: </strong>This study was a retrospective cohort assessing the efficacy of direct oral anticoagulants (Dabigatran or Rivaroxaban) on the resolution of left ventricular thrombus in patients taking either of these drugs during the study period from December, 2011 to December, 2016 at King Fahad Medical City. All patients' records were reviewed and all patients who were diagnosed with left ventricular thrombus were included. Patients without available echocardiogram records were excluded. The study was approved by the institutional review board of King Fahad medical city, Riyadh Saudi Arabia.</p><p><strong>Result: </strong>During the defined study period we found that 413 and 1218 patients were taking Dabigatran and Rivaroxaban, respectively. After filtering them based on the specialty of the prescriber, we ended up with 299 patients who have been started on Dabigatran and 448 patients who have been started on Rivaroxaban by cardiologists. Moreover, after reviewing echocardiogram reports for all of them (747 patients), we found that 11 patients were diagnosed to have left ventricular thrombus. Among those 11 patients, seven of them were treated with direct oral anticoagulants from the beginning and the remaining four patients were shifted from Warfarin to direct oral anticoagulants. All of them (7 patients) showed left ventricular thrombus resolution on follow-up echocardiogram.</p><p><strong>Conclusion: </strong>Use of direct oral anticoagulants showed promising results in the resolution of left ventricular thrombus in patients diagnosed with left ventricular thrombus. Further studies at multiple health care centers are needed to further evaluate the efficacy and safety of direct oral anticoagulants as compared to traditional treatment in patients with left ventricular thrombus.</p>","PeriodicalId":30457,"journal":{"name":"JRSM Cardiovascular Disease","volume":"8 ","pages":"2048004019839548"},"PeriodicalIF":1.4000,"publicationDate":"2019-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2048004019839548","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JRSM Cardiovascular Disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2048004019839548","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 14

Abstract

Background: Left ventricular thrombus is a frequent complication of acute myocardial infarction and a risk factor for thromboembolic complications. Warfarin has been frequently used, but has some disadvantages that limit its use. Direct oral anticoagulants, in particular Dabigatran and Rivaroxaban have been proved to be effective in preventing thromboembolism among patients with non-valvular atrial fibrillation. However, no randomized clinical trials testing the efficacy and safety of these agents in patients with existing left ventricular thrombus. Furthermore, direct oral anticoagulants are still not approved by the Food and Drug Administration in the management of left ventricular thrombus.

Method: This study was a retrospective cohort assessing the efficacy of direct oral anticoagulants (Dabigatran or Rivaroxaban) on the resolution of left ventricular thrombus in patients taking either of these drugs during the study period from December, 2011 to December, 2016 at King Fahad Medical City. All patients' records were reviewed and all patients who were diagnosed with left ventricular thrombus were included. Patients without available echocardiogram records were excluded. The study was approved by the institutional review board of King Fahad medical city, Riyadh Saudi Arabia.

Result: During the defined study period we found that 413 and 1218 patients were taking Dabigatran and Rivaroxaban, respectively. After filtering them based on the specialty of the prescriber, we ended up with 299 patients who have been started on Dabigatran and 448 patients who have been started on Rivaroxaban by cardiologists. Moreover, after reviewing echocardiogram reports for all of them (747 patients), we found that 11 patients were diagnosed to have left ventricular thrombus. Among those 11 patients, seven of them were treated with direct oral anticoagulants from the beginning and the remaining four patients were shifted from Warfarin to direct oral anticoagulants. All of them (7 patients) showed left ventricular thrombus resolution on follow-up echocardiogram.

Conclusion: Use of direct oral anticoagulants showed promising results in the resolution of left ventricular thrombus in patients diagnosed with left ventricular thrombus. Further studies at multiple health care centers are needed to further evaluate the efficacy and safety of direct oral anticoagulants as compared to traditional treatment in patients with left ventricular thrombus.

Abstract Image

Abstract Image

Abstract Image

直接口服抗凝剂治疗左室血栓的疗效——病例系列及文献复习。
背景:左心室血栓是急性心肌梗死的常见并发症,也是血栓栓塞并发症的危险因素。华法林已被广泛使用,但有一些缺点,限制了它的使用。直接口服抗凝剂,特别是达比加群和利伐沙班已被证明可有效预防非瓣膜性心房颤动患者的血栓栓塞。然而,没有随机临床试验测试这些药物对现有左心室血栓患者的有效性和安全性。此外,直接口服抗凝剂仍未被食品和药物管理局批准用于左心室血栓的治疗。方法:采用回顾性队列研究方法,评价2011年12月至2016年12月法赫德国王医疗城患者口服直接抗凝药物达比加群或利伐沙班对左室血栓的溶解效果。我们回顾了所有患者的记录,并纳入了所有诊断为左心室血栓的患者。排除无超声心动图记录的患者。这项研究得到了沙特阿拉伯利雅得法赫德国王医疗城机构审查委员会的批准。结果:在规定的研究期间,我们发现有413例和1218例患者分别服用达比加群和利伐沙班。在根据开处方者的专业进行筛选后,我们最终得到299名患者开始使用达比加群,448名患者开始使用利伐沙班。此外,在回顾了所有患者(747例)的超声心动图报告后,我们发现11例患者被诊断为左心室血栓。11例患者中,7例患者一开始使用直接口服抗凝药物,其余4例患者由华法林改为直接口服抗凝药物。7例患者随访超声心动图均显示左室血栓消退。结论:在诊断为左室血栓的患者中,直接口服抗凝剂治疗左室血栓有良好的效果。需要在多个卫生保健中心进行进一步的研究,以进一步评估直接口服抗凝剂与传统治疗相比对左室血栓患者的疗效和安全性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JRSM Cardiovascular Disease
JRSM Cardiovascular Disease CARDIAC & CARDIOVASCULAR SYSTEMS-
自引率
6.20%
发文量
12
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信